Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: a year ago

Possible Interaction: Cannabinoids and Rimonabant

supplement:

Cannabinoids

Research Papers that Mention the Interaction

All these … CB1 antagonist rimonabant , suggesting … of CB1 blockade is due not only to the transient suppression of food intake and reduction of lipogenesis but also to an increased … which counteracts the inhibitory effects of ECs, levels of which are increased in fat tissues of obese rodents and humans.
Best practice & research. Clinical endocrinology & metabolism  •  2009  |  View Paper
Although not affecting most cannabinoid effects in the airways, rimonabant counteracts inhibition of smooth-muscle contraction by cannabinoids in urogenital tissues and may interfere with embryo attachment and outgrowth of blastocysts.
Naunyn-Schmiedeberg's Archives of Pharmacology  •  2008  |  View Paper
The blockade of the cannabinoid system (CB1) by the specific inhibitor ( rimonabant ) decreases food intake and adiposity in animals and in humans.
Revue medicale de Bruxelles  •  2005  |  View Paper
Rimonabant acts as an antagonist at the cannabinoid-1 (CB-1) receptor which is expressed on adipocytes.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association  •  2011  |  View Paper
Rimonabant is a selective antagonist of the cannabinoid type 1 (CB1) receptor, part of the endocannabinoid system that plays a significant role in regulating the drive for food ingestion.
JAMA  •  2008  |  View Paper
Rimonabant is a selective blocker of cannabinoid-1 (CB1) receptors and participates in the regulation of impaired endocannabinoid system.
Casopis lekaru ceskych  •  2005  |  View Paper
The blockade of the cannabinoid system (CB1) by the specific inhibitor ( rimonabant ) decreases food intake and adiposity in animals and in humans.
Journal de pharmacie de Belgique  •  2005  |  View Paper
…,N-(piperidiny-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide ( SR141716A) … cannabinoid (CB) agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-…-2), and behaves as an inverse agonist by producing opposite current effects when applied alone.
Molecular pharmacology  •  2002  |  View Paper
The cannabinoid inverse agonist rimonabant antagonized the hypothermic effect of all compounds.
Drug and alcohol dependence  •  2017  |  View Paper
The CB1 antagonist/inverse agonist AM251 [ N-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide ] blocked these responses.
The Journal of Neuroscience  •  2014  |  View Paper
Show More